Cellect Biotechnology Ltd (APOP) EPS Estimated At $-0.22

August 9, 2017 - By Linda Rogers

 Cellect Biotechnology Ltd (APOP) EPS Estimated At $ 0.22

Analysts await Cellect Biotechnology Ltd (TLV:APOP) to report earnings on September, 7. They expect $-0.22 earnings per share, down 2,100.00 % or $0.21 from last year’s $-0.01 per share. After $-0.04 actual earnings per share reported by Cellect Biotechnology Ltd for the previous quarter, Wall Street now forecasts 450.00 % negative EPS growth. The stock decreased 0.08% or $0.1 on August 9, reaching $118.4. About 154,194 shares traded. Cellect Biotechnology Ltd (TLV:APOP) has 0.00% since August 9, 2016 and is . It has underperformed by 16.70% the S&P500.

Cellect Biotechnology Ltd, formerly Cellect Biomed Ltd, is an Israel firm engaged in regenerative medicine through the development of products facilitating immune stem cell selection. The company has market cap of $129.32 million. The Company’s platform technology is based on the game changing perception that the functional properties of stem cells rather than appearance should be used for their identification, selection and utilization. It currently has negative earnings. The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents.

More notable recent Cellect Biotechnology Ltd (TLV:APOP) news were published by: Quotes.Wsj.com which released: “Cellect Biotechnology Ltd. ADR” on July 29, 2016, also Marketwatch.com with their article: “6.63” published on July 29, 2016, Investorplace.com published: “Why Cellect Biotechnology Ltd. (APOP) Stock Is Soaring Today” on March 27, 2017. More interesting news about Cellect Biotechnology Ltd (TLV:APOP) were released by: Fool.com and their article: “Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today” published on February 08, 2017 as well as Globenewswire.com‘s news article titled: “Cellect Biotechnology Ltd Provides Corporate Update and Reports Third Quarter …” with publication date: November 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.